Human Genome Epidemiology Literature Finder
Records 1 - 30 (of 129 Records) |
Query Trace: Thoracic Neoplasms and Egfr[original query] |
---|
Retrospective analysis of independent predictors of progression-free survival in patients with EGFR mutation-positive advanced non-small cell lung cancer receiving first-line osimertinib. Thoracic cancer 2022 Aug . Teranishi Shuhei, Sugimoto Chihiro, Nagaoka Satoshi, Nagayama Hirokazu, Segawa Wataru, Miyasaka Atsushi, Hiro Shuntaro, Kajita Yukihito, Maeda Chihiro, Kobayashi Nobuaki, Yamamoto Masaki, Kudo Makoto, Kaneko Takes |
The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non-small cell lung cancer: A real-world study. Thoracic cancer 2022 9 13 (18): 2641-2649. Feng Yu, Huang Liling, Zhu Haohua, Tang Le, Hu Xingsheng, Shi Yuank |
Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non-small cell lung cancer. Thoracic cancer 2022 Sep . Chang Geyun, Li Weihua, Bai Hua, Duan Jianchun, Wang Zhijie, Du Xinyang, Yu Ruofei, Wang Yaxi, Wang Minghao, Zhu Yixiang, Zhang Xue, Li Li, Wan Rui, Wang J |
Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity-matched analysis in a cohort of 147 recurrences. Thoracic cancer 2022 Sep . Xu Fei, Chen Heng-Chi, Xu Haiyan, Li Junling, Hao Xuezhi, Xing Puyuan, Ying Jianming, Wang Y |
A case of multiple primary lung adenocarcinoma with a CD74-NRG1 fusion protein and HER2 mutation benefit from combined target therapy. Thoracic cancer 2022 9 13 (21): 3063-3067. Chen Kai, Li Wen, Xi Xiaoming, Zhong J |
Genotyping of cerebrospinal fluid in lung cancer patients with leptomeningeal metastasis. Thoracic cancer 2022 Sep 13 (18): 2574-2583. Nie Naifu, Zhou Haodong, Zhang Kejun, Liu Lan, Luo Nuo, Wang Renyuan, Li Xin, Zhu Mengxiao, Hu Chen, Wang Yubo, Liu Zhulin, Li Li, He Yo |
Endobronchial ultrasound-guided re-biopsy of non-small cell lung cancer with acquired resistance after EGFR tyrosine kinase inhibitor treatment. Thoracic cancer 2022 12 14 (4): 363-370. Hong Kyung Soo, Cho Jinmo, Jang Jong Geol, Jang Min Hye, Ahn June Ho |
Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan. Thoracic cancer 2022 11 14 (1): 12-23. Chang John Wen-Cheng, Huang Chen-Yang, Fang Yueh-Fu, Chang Ching-Fu, Yang Cheng-Ta, Kuo Chih-Hsi Scott, Hsu Ping-Chih, Wu Chiao- |
Real-world outcomes of anti-EGFR therapy in advanced non-small cell lung cancer EGFR mutated in Peru. Thoracic cancer 2022 11 14 (1): 61-67. Galvez-Nino Marco, Ruiz Rossana, Roque Katia, Coanqui Ofelia, Valdivieso Natalia, Olivera Mivael, Ganti Apar Kishor, Mas Lu |
Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations. Thoracic cancer 2022 10 13 (22): 3217-3224. Murakami Shuji, Yokose Tomoyuki, Shinada Kanako, Isaka Testuya, Katakura Kengo, Ushio Ryouta, Kondo Tetsuro, Kato Terufumi, Ito Hiroyuki, Saito Haruhi |
ERBB2 exon 20 insertions are rare in Brazilian non-small cell lung cancer. Thoracic cancer 2022 Oct . de Oliveira Cavagna Rodrigo, Zaniolo Beatriz Garbe, de Paula Flávia Escremim, Berardinelli Gustavo Noriz, Santana Iara, da Silva Eduardo Caetano Albino, Dias Josiane Mourão, Jacinto Alexandre Arthur, da Nóbrega Oliveira Rachid Eduardo Noleto, de Marchi Pedro, Leal Letícia Ferro, Reis Rui Manu |
Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs. Thoracic cancer 2023 9 . Huang-Chih Chang, Chin-Chou Wang, Chia-Cheng Tseng, Kuo-Tung Huang, Yu-Mu Chen, Yu-Ping Chang, Chien-Hao Lai, Wen-Feng Fang, Meng-Chih Lin, Hung-Yi Chua |
Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors: A single-center ambispective cohort study. Thoracic cancer 2023 9 . Yangchun Gu, Jinyu Yu, Haifeng Hu, Hua Zhang, Baoshan Cao, Li Lia |
Survival outcomes of east Asian patients with advanced non-small cell lung cancer treated with first-line EGFR tyrosine kinase inhibitors: A network meta-analysis of real-world evidence. Thoracic cancer 2023 9 . Huang-Chih Chang, Kuo-Tung Huang, Chia-Cheng Tseng, Yu-Mu Chen, Chien-Hao Lai, Yu-Ping Chang, Yung-Che Chen, Hung-Yi Chuang, Chin-Chou Wa |
Nivolumab as maintenance therapy following platinum-based chemotherapy in EGFR-mutant lung cancer patients after tyrosine kinase inhibitor failure: A single-arm, open-label, phase 2 trial. Thoracic cancer 2023 9 . Jiwon Kim, Chang-Min Choi, Wonjun Ji, Jae Cheol L |
Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M-positive: Case report and literature review. Thoracic cancer 2023 8 . Chihiro Maeda, Kanako Shinada, Shuji Murakami, Haruhiro Sai |
Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer. Thoracic cancer 2023 7 . Si-Yu Lei, Hai-Yan Xu, Hong-Shuai Li, Ya-Ning Yang, Fei Xu, Jun-Ling Li, Zhi-Jie Wang, Pu-Yuan Xing, Xue-Zhi Hao, Yan Wa |
Genetic dissection of intratumor heterogeneity of PD-L1 expression in EGFR-mutated lung adenocarcinoma. Thoracic cancer 2023 7 . Kei Kunimasa, Yosuke Hirotsu, Kenji Amemiya, Keiichiro Honma, Harumi Nakamura, Kazumi Nishino, Masao Oma |
Chemotherapy outcomes in EGFR-TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort study. Thoracic cancer 2023 5 . Chien-Yu Lin, Chia-Hao Hu, Chia-Fu Hsu, Jeng-Shiuan Tsai, Chian-Wei Chen, Chia-Yin Lin, Chao-Chun Chang, Yi-Ting Yen, Yau-Lin Tseng, Po-Lan Su, Chien-Chung L |
Osimertinib combined with bevacizumab as the first-line treatment in non-small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations. Thoracic cancer 2023 4 . Zhang Ling, You Yunhong, Liu Xueli, Liu Fengjuan, Nie Keke, Ji Youx |
Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non-small cell lung cancer patients with EGFR mutation: A multicenter retrospective study. Thoracic cancer 2023 3 . Hata Tae, Sakaguchi Chikara, Hirano Keita, Kobe Hiroshi, Ishida Masaki, Nakano Takayuki, Tachibana Yusuke, Tamiya Nobuyo, Shiotsu Shinsuke, Takeda Takayuki, Yamada Tadaaki, Yokoyama Toshihide, Tsuchiya Michiko, Nagasaka Yuk |
Transient asymptomatic pulmonary opacities in a patient with MET exon 14 skipping non-small cell lung cancer: A case report. Thoracic cancer 2023 2 . Ikeo Satoshi, Yasuda Naoaki, Sakai Yuki, Hayashi Yasuyuki, Sokai Akihiko, Iwata Toshiyuki, Nishimura Takas |
The oncogenic role of LGR6 overexpression induced by aberrant Wnt/?-catenin signaling in lung cancer. Thoracic cancer 2023 11 . Noriaki Sunaga, Kyoichi Kaira, Kimihiro Shimizu, Ichidai Tanaka, Yosuke Miura, Seshiru Nakazawa, Yoichi Ohtaki, Reika Kawabata-Iwakawa, Mitsuo Sato, Luc Girard, John D Minna, Takeshi Hisa |
Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non-small cell lung cancer. Thoracic cancer 2023 10 . Binyang Pan, Jiaqi Liang, Haochun Shi, Kungeng Rao, Weigang Guo, Cheng Zh |
Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR-TKIs in advanced non-small cell lung cancer: A systematic review and network meta-analysis. Thoracic cancer 2023 1 14 (6): 535-543. Dai Jiali, Liu Xinyin, Li Jun, Qu Tianyu, Cui Yanan, Jin Shidai, Zhang Erbao, Guo Renh |
Old age and EGFR mutation status in inoperable early-stage non-small cell lung cancer patients receiving stereotactic ablative radiotherapy: A single institute experience of 71 patients in Taiwan. Thoracic cancer 2023 1 14 (7): 654-661. Wu Yuan-Hung, Kang Yu-Mei, Hu Yu-Wen, Lan Keng-Li, Yen Sang-Hue, Lai Tzu-Yu, Lan Tien-Li, Chen Yuh-Min, Chiu Chao-Hua, Luo Yung-Hung, Chao Heng-Sheng, Chiang Chi-Lu, Shiao Tsu-Hui, Yang Chao-Neng, Hsu Wen-Hu, Wu Yu-Chung, Hsu Han-Shui, Hung Jung-Jyh, Huang Chien-Sheng, Hsu Po-Kuei, Chen Yi-W |
Efficacy and safety of 40?mg osimertinib administered every other day for non-small cell lung cancer harboring an epidermal growth factor receptor mutation: A single-center retrospective cohort study. Thoracic cancer 2024 1 . Ayumu Otsuki, Naoki Inoshima, Kentaro Tochigi, Hiroyuki Ito, Kei Nakashi |
Factors associated with prolonged progression-free survival of patients treated with first-line afatinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer. Thoracic cancer 2024 1 . Li-Chung Chiu, Ping-Chih Hsu, Chin-Chou Wang, How-Wen Ko, Scott Chih-Hsi Kuo, Jia-Shiuan Ju, Pi-Hung Tung, Allen Chung-Cheng Huang, Cheng-Ta Ya |
Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion. Thoracic cancer 2024 1 . Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nish |
Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with "adenocarcinoma" and "non-small cell carcinoma favor adenocarcinoma". Thoracic cancer 2024 1 . Naoko Shigeta, Tomoyuki Yokose, Shuji Murakami, Tetsuya Isaka, Kanako Shinada, Emi Yoshioka, Atsuya Narita, Kengo Katakura, Tetsuro Kondo, Terufumi Kato, Takuya Nagashima, Haruhiro Saito, Hiroyuki I |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 06, 2024
- Content source: